
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5996014/publications.pdf Version: 2024-02-01



ΡΛΙΙΙ Ι \λ/μιτε

#	Article	IF	CITATIONS
1	Problem solving in chemistry supported by metacognitive scaffolding: teaching associates' perspectives and practices. Chemistry Education Research and Practice, 2022, 23, 436-451.	1.4	6
2	Cultural adaptation and validation of instruments for measuring the flipped classroom experience. Currents in Pharmacy Teaching and Learning, 2022, 14, 23-32.	0.4	2
3	¹¹³ Cd as a Probe in NMR Studies of Allosteric Hostâ€Guestâ€Ligand Complexes of Porphyrin Cage Compounds. European Journal of Organic Chemistry, 2022, 2022, .	1.2	0
4	Host–Guest Exchange of Viologen Guests in Porphyrin Cage Compounds as Studied by Selective Exchange Spectroscopy (1D EXSY) NMR. Angewandte Chemie - International Edition, 2021, 60, 1254-1262.	7.2	11
5	Host–Guest Exchange of Viologen Guests in Porphyrin Cage Compounds as Studied by Selective Exchange Spectroscopy (1D EXSY) NMR. Angewandte Chemie, 2021, 133, 1274-1282.	1.6	3
6	Pharmacological Insights Into Safety and Efficacy Determinants for the Development of Adenosine Receptor Biased Agonists in the Treatment of Heart Failure. Frontiers in Pharmacology, 2021, 12, 628060.	1.6	5
7	Biased agonism at adenosine receptors. Cellular Signalling, 2021, 82, 109954.	1.7	22
8	Identifying the core concepts of pharmacology education. Pharmacology Research and Perspectives, 2021, 9, e00836.	1.1	12
9	Development of a Vertically Integrated Pharmacy Degree. Pharmacy (Basel, Switzerland), 2021, 9, 156.	0.6	7
10	Positive allosteric mechanisms of adenosine A1 receptor-mediated analgesia. Nature, 2021, 597, 571-576.	13.7	84
11	Defining and unpacking the core concepts of pharmacology education. Pharmacology Research and Perspectives, 2021, 9, e00894.	1.1	14
12	Engaging older people as university-based instructors: A model to improve the empathy and attitudes of pharmacists in training. Currents in Pharmacy Teaching and Learning, 2020, 12, 58-64.	0.4	14
13	Predictors of Pharmacy Student Performance on Written and Clinical Examinations in a Flipped Classroom Curriculum. American Journal of Pharmaceutical Education, 2020, 84, 8038.	0.7	10
14	The adenosine A2B G protein-coupled receptor: Recent advances and therapeutic implications. , 2019, 198, 20-33.		34
15	New paradigms in adenosine receptor pharmacology: allostery, oligomerization and biased agonism. British Journal of Pharmacology, 2018, 175, 4036-4046.	2.7	49
16	A Structure–Activity Relationship Study of Bitopic <i>N</i> ⁶ -Substituted Adenosine Derivatives as Biased Adenosine A ₁ Receptor Agonists. Journal of Medicinal Chemistry, 2018, 61, 2087-2103.	2.9	29
17	α 1A -Adrenoceptors activate mTOR signalling and glucose uptake in cardiomyocytes. Biochemical Pharmacology, 2018, 148, 27-40.	2.0	20
18	Development of a self-report instrument for measuring in-class student engagement reveals that pretending to engage is a significant unrecognized problem. PLoS ONE, 2018, 13, e0205828.	1.1	25

#	Article	IF	CITATIONS
19	Effect of the 5-HT4 receptor agonist tegaserod on the expression of GRK2 and GRK6 in the rat gastrointestinal tract. BMC Research Notes, 2018, 11, 362.	0.6	4
20	Self-Crosslinking Lipopeptide/DNA/PEGylated Particles: A New Platform for DNA Vaccination Designed for Assembly in Aqueous Solution. Molecular Therapy - Nucleic Acids, 2018, 12, 504-517.	2.3	10
21	Student engagement with a flipped classroom teaching design affects pharmacology examination performance in a manner dependent on question type. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-7-7.	0.0	0
22	Adenosine G Proteinâ€Coupled Receptor Biased Agonism to Treat Ischemic Heart Disease. FASEB Journal, 2018, 32, 555.19.	0.2	0
23	Capadenoson, a clinically trialed partial adenosine A 1 receptor agonist, can stimulate adenosine A 2B receptor biased agonism. Biochemical Pharmacology, 2017, 135, 79-89.	2.0	37
24	Student Engagement with a Flipped Classroom Teaching Design Affects Pharmacology Examination Performance in a Manner Dependent on Question Type. American Journal of Pharmaceutical Education, 2017, 81, 5931.	0.7	39
25	Targeting Adenosine Receptors for the Treatment of Cardiac Fibrosis. Frontiers in Pharmacology, 2017, 8, 243.	1.6	42
26	A suicidal strain of Listeria monocytogenes is effective as a DNA vaccine delivery system for oral administration. Vaccine, 2017, 35, 5115-5122.	1.7	13
27	Tissue-specific Calibration of Real-time PCR Facilitates Absolute Quantification of Plasmid DNA in Biodistribution Studies. Molecular Therapy - Nucleic Acids, 2016, 5, e371.	2.3	1
28	Extracellular Loop 2 of the Adenosine A1 Receptor Has a Key Role in Orthosteric Ligand Affinity and Agonist Efficacy. Molecular Pharmacology, 2016, 90, 703-714.	1.0	53
29	Role of the Second Extracellular Loop of the Adenosine A ₁ Receptor on Allosteric Modulator Binding, Signaling, and Cooperativity. Molecular Pharmacology, 2016, 90, 715-725.	1.0	56
30	Novel Irreversible Agonists Acting at the A ₁ Adenosine Receptor. Journal of Medicinal Chemistry, 2016, 59, 11182-11194.	2.9	20
31	Developing a Framework for Objective Structured Clinical Examinations Using the Nominal Group Technique. American Journal of Pharmaceutical Education, 2016, 80, 158.	0.7	12
32	Adopting an active learning approach to teaching in a research-intensive higher education context transformed staff teaching attitudes and behaviours. Higher Education Research and Development, 2016, 35, 619-633.	1.9	73
33	<scp>VCP</scp> 746, a novel A ₁ adenosine receptor biased agonist, reduces hypertrophy in a rat neonatal cardiac myocyte model. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 976-982.	0.9	20
34	The hybrid molecule, VCP746, is a potent adenosine A2B receptor agonist that stimulates anti-fibrotic signalling. Biochemical Pharmacology, 2016, 117, 46-56.	2.0	30
35	Ligand-Independent Adenosine A2B Receptor Constitutive Activity as a Promoter of Prostate Cancer Cell Proliferation. Journal of Pharmacology and Experimental Therapeutics, 2016, 357, 36-44.	1.3	50
36	Flipped Classroom Implementation: A Case Report of Two Higher Education Institutions in the United States and Australia. Computers in the Schools, 2016, 33, 24-37.	0.4	56

#	Article	IF	CITATIONS
37	Quantification of adenosine A 1 receptor biased agonism: Implications for drug discovery. Biochemical Pharmacology, 2016, 99, 101-112.	2.0	58
38	Synthesis of six mexiletine derivatives with isoindolines attached as potential antioxidants and their evaluation as cardioprotective agents. MedChemComm, 2015, 6, 634-639.	3.5	2
39	Buccal mucosal delivery of a potent peptide leads to therapeutically-relevant plasma concentrations for the treatment of autoimmune diseases. Journal of Controlled Release, 2015, 199, 37-44.	4.8	26
40	Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4614-4619.	3.3	92
41	<scp>HCN</scp> channelopathy and cardiac electrophysiologic dysfunction in genetic and acquired rat epilepsy models. Epilepsia, 2014, 55, 609-620.	2.6	29
42	An Allosteric Modulator of the Adenosine A1 Receptor Improves Cardiac Function Following Ischaemia in Murine Isolated Hearts. Pharmaceuticals, 2013, 6, 546-556.	1.7	12
43	Colloidal characteristics and formulation of pure protein particulate vaccines. Journal of Pharmacy and Pharmacology, 2012, 64, 1386-1393.	1.2	2
44	Synthesis and Pharmacological Evaluation of Dual Acting Antioxidant A _{2A} Adenosine Receptor Agonists. Journal of Medicinal Chemistry, 2012, 55, 3521-3534.	2.9	17
45	Enhanced Extravasation, Stability and <i>in Vivo</i> Cardiac Gene Silencing via <i>in Situ</i> siRNA–Albumin Conjugation. Molecular Pharmaceutics, 2012, 9, 71-80.	2.3	41
46	Synthesis and Biological Evaluation of Adenosines with Heterobicyclic and Polycyclic <i>N</i> ⁶ â€6ubstituents as Adenosine A ₁ Receptor Agonists. ChemMedChem, 2012, 7, 1191-1201.	1.6	5
47	Edaravone containing isoindoline nitroxides for the potential treatment of cardiovascular ischaemia. MedChemComm, 2011, 2, 436.	3.5	27
48	Commercially Supplied Amine-Modified siRNAs May Require Ultrafiltration prior to Conjugation with Amine-Reactive Compounds. Journal of Nucleic Acids, 2011, 2011, 1-5.	0.8	3
49	Tissue dependent differences in G-protein coupled receptor kinases associated with 5-HT4 receptor desensitization in the rat gastro-intestinal tract. Biochemical Pharmacology, 2011, 81, 123-133.	2.0	10
50	A Novel Highly Selective Adenosine A1 Receptor Agonist VCP28 Reduces Ischemia Injury in a Cardiac Cell Line and Ischemia–Reperfusion Injury in Isolated Rat Hearts at Concentrations That Do Not Affect Heart Rate. Journal of Cardiovascular Pharmacology, 2010, 56, 282-292.	0.8	14
51	Cooperative Cardioprotection Through Adenosine A1 and A2A Receptor Agonism in Ischemia-Reperfused Isolated Mouse Heart. Journal of Cardiovascular Pharmacology, 2010, 56, 379-388.	0.8	25
52	Interaction of viruses with host cell molecular motors. Current Opinion in Biotechnology, 2010, 21, 633-639.	3.3	29
53	Synthesis and evaluation of new N6-substituted adenosine-5′-N-methylcarboxamides as A3 adenosine receptor agonists. Bioorganic and Medicinal Chemistry, 2010, 18, 3078-3087.	1.4	10
54	Delineating the Mode of Action of Adenosine A ₁ Receptor Allosteric Modulators. Molecular Pharmacology, 2010, 78, 444-455.	1.0	39

#	Article	IF	CITATIONS
55	Binding Mode Prediction of PDE4 Inhibitors: A Comparison of Modelling Methods. Australian Journal of Chemistry, 2010, 63, 396.	0.5	3
56	Use of Kv1.3 Blockers for Inflammatory Skin Conditions. Current Medicinal Chemistry, 2010, 17, 2882-2896.	1.2	17
57	Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides. Expert Reviews in Molecular Medicine, 2009, 11, e10.	1.6	50
58	Cardioprotection Induced by Adenosine A1 Receptor Agonists in a Cardiac Cell Ischemia Model Involves Cooperative Activation of Adenosine A2A and A2B Receptors by Endogenous Adenosine. Journal of Cardiovascular Pharmacology, 2009, 53, 424-433.	0.8	31
59	A Faculty Approach to Implementing Advanced, E-Learning Dependent, Formative and Summative Assessment Practices. Advances in Information and Communication Technology Education Series, 2009, , 76-96.	0.1	2
60	BARRIERS TO SUCCESSFUL DELIVERY OF SHORT INTERFERING RNA AFTER SYSTEMIC ADMINISTRATION. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 1371-1376.	0.9	56
61	Dual acting antioxidant A1 adenosine receptor agonists. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5437-5441.	1.0	20
62	Comparison of opioid receptor distributions in the rat ileum. Life Sciences, 2006, 78, 1610-1616.	2.0	20
63	Comparison of opioid receptor distributions in the rat central nervous system. Life Sciences, 2006, 79, 674-685.	2.0	36
64	CHARACTERIZATION OF THE ACUTE CARDIOVASCULAR EFFECTS OF INTRAVENOUSLY ADMINISTERED INSULIN-LIKE GROWTH FACTOR-I IN CONSCIOUS SPRAGUE-DAWLEY RATS. Clinical and Experimental Pharmacology and Physiology, 2006, 33, 1190-1195.	0.9	5
65	Intravenous Insulin-like Growth Factor-I Receptor Antisense Treatment Reduces Angiotensin Receptor Expression and Function in Spontaneously Hypertensive Rats. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 1171-1177.	1.3	17
66	Characterisation of opioid receptors involved in modulating circular and longitudinal muscle contraction in the rat ileum. British Journal of Pharmacology, 2005, 144, 687-694.	2.7	21
67	Intravenous IGF-I receptor antisense reduces IGF-IR expression and diminishes pressor responses to angiotensin II in conscious normotensive rats. British Journal of Pharmacology, 2005, 146, 935-941.	2.7	7
68	Antisense oligonucleotide treatments for psoriasis. Expert Opinion on Biological Therapy, 2004, 4, 75-81.	1.4	17
69	Sequence Dependence of C5-Propynyl-dU,dC-Phosphorothioate Oligonucleotide Inhibition of the Human IGF-I Receptor: mRNA, Protein, and Cell Growth. Oligonucleotides, 2002, 12, 369-377.	4.4	4
70	Chronic Caffeine Treatment Causes Changes in Cardiac Adenosine Receptor Function in Rats. Pharmacology, 2002, 65, 129-135.	0.9	14
71	C-5 Propyne-Modified Oligonucleotides Penetrate the Epidermis in Psoriatic and Not Normal Human Skin After Topical Application. Journal of Investigative Dermatology, 2002, 118, 1003-1007.	0.3	20

Antisense oligonucleotides in cutaneous therapy. , 2001, 90, 89-104.

PAUL J WHITE

#	Article	IF	CITATIONS
73	Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides. Nature Biotechnology, 2000, 18, 521-526.	9.4	81
74	Antisense Inhibition of IGF Receptor Expression in HaCaT Keratinocytes: A Model for Antisense Strategies in Keratinocytes. Oligonucleotides, 2000, 10, 195-203.	4.4	12
75	Oligonucleotide Uptake in Cultured Keratinocytes: Influence of Confluence, Cationic Liposomes, and Keratinocyte Cell Type. Journal of Investigative Dermatology, 1999, 112, 699-705.	0.3	25
76	Live Confocal Microscopy of Oligonucleotide Uptake by Keratinocytes in Human Skin Grafts on Nude Mice. Journal of Investigative Dermatology, 1999, 112, 887-892.	0.3	42
77	Intranuclear Localization of Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3) During Cell Division in Human Keratinocytes. Journal of Investigative Dermatology, 1998, 111, 239-242.	0.3	62
78	Functional characterization of adenosine receptors in the nucleus tractus solitarius mediating hypotensive responses in the rat. British Journal of Pharmacology, 1996, 117, 305-308.	2.7	23
79	Changes in adenosine receptors mediating hypotension in morphine-dependent rats. European Journal of Pharmacology, 1995, 294, 215-220.	1.7	8
80	The role of adenosine in the hypotensive actions of morphine. European Journal of Pharmacology, 1995, 286, 315-319.	1.7	4
81	Examining the Role of the Linker in Bitopic <i>N</i> ⁶ -Substituted Adenosine Derivatives Acting as Biased Adenosine A ₁ Receptor Agonists. Journal of Medicinal Chemistry, 0, , .	2.9	1